Abbott Laboratories reported a strong Q2 performance, beating earnings expectations and raising its full-year guidance. The company's acquisition of Exact Sciences is expected to boost long-term growth, supporting a projected 10.4% compound annual growth rate (CAGR) over the next six years. Despite recent stock price gains, Abbott trades below its 5-year forward price-to-earnings average and offers a 2.5% dividend yield with a potential 37% upside to a $151 price target. Risks include volatility in its Nutrition segment, regulatory challenges, and international exposure, but its strong credit rating and Dividend King status support a premium valuation.
The National Association of Community Health Centers (NACHC) and Abbott have launched a multi-year "Food for Health" initiative to make nutrition a core part of primary care at over 1,500 Community Health Centers across the U.S. This program includes...
MiniMed has launched its MiniMed Flex system in the U.S., featuring the Instinct sensor made by Abbott. This system is notable for being MiniMed's smallest insulin pump that can be controlled via an app, paired with the world's smallest sensor that l...
